These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1932220)

  • 1. Use of blood and blood products for supportive care in cancer treatment.
    Wallerstein R; Deisseroth AB
    Curr Opin Oncol; 1991 Aug; 3(4):628-33. PubMed ID: 1932220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM; Cannon A; Mitchum EN
    Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. The use of platelet transfusions.
    Feusner J
    Am J Pediatr Hematol Oncol; 1984; 6(3):255-60. PubMed ID: 6393789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of refractoriness to platelet transfusion.
    Schiffer CA
    Blood Rev; 2001 Dec; 15(4):175-80. PubMed ID: 11792118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing platelet transfusion therapy.
    Heal JM; Blumberg N
    Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of platelets and other transfusion products in patients with malignancy.
    Bayer WL; Bodensteiner DC; Tilzer LL; Adams ME
    Semin Thromb Hemost; 1992; 18(4):380-91. PubMed ID: 1470926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet transfusion and alternatives to transfusion in patients with malignancy.
    Vaickus L; Breitmeyer JB; Schlossman RL; Anderson KC
    Stem Cells; 1995 Nov; 13(6):588-96. PubMed ID: 8590860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 1990 Feb; 4(1):291-311. PubMed ID: 2179213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune globulin therapy in allogeneic bone marrow transplant: a critical review.
    Guglielmo BJ; Wong-Beringer A; Linker CA
    Bone Marrow Transplant; 1994 May; 13(5):499-510. PubMed ID: 8054903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet transfusion. Current techniques, remaining problems, and future prospects.
    Herman JH; Kamel HT
    Am J Pediatr Hematol Oncol; 1987; 9(3):272-86. PubMed ID: 3314551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of leukocyte-reduced blood components.
    Miller JP; Mintz PD
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
    Toor AA; Choo SY; Little JA
    Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloimmunization following platelet transfusions in patients with acute nonlymphocytic leukemia.
    Nozaki H; Shimizu M; Komatsuda M; Watanabe K; Nagao T; Arimori S
    Tokai J Exp Clin Med; 1986 Aug; 11(3):201-4. PubMed ID: 3475819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F
    Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.